Sutacimig

N/A

Report date: 2025/06/26 15:35:40

Base Information

Drug NameSutacimig
Drug Alias NameHMB001HMB-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionFactor VIIa modulatorsAnti-TREML1
TargetsCoagulation factor VIITrem-like transcript 1 protein
Therapy Area/IndicationsThrombastheniaFactor VII Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHemab Therapeutics APS
China Registration ClassN/A

Develop Information

Active CompaniesHemab APSHemab Therapeutics APS
Inactive CompaniesN/A
Active IndicationsThrombastheniaFactor VII Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A